ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tonlamarsen

Also written as “Tonlamarsen” and “ION904”.

Its studies are mostly in Hypertension · Hypertensive Crisis, led by 2 companies.

Drug pageTonlamarsen: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 29, 20224 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ionis Pharmaceuticalsits history only20 open or runningphase 2since Mar 29, 2022Jan 26, 2021none ahead
Kardigan21 open or runningphase 2since Feb 12, 2025Feb 12, 2025Dec 2026phase 2 · NCT07511361

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kardigan only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2022Named tonlamarsenINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ION904
  2. Feb 12, 2025First study: phase 2 study in HypertensionFirst studyNCT06864104 · 206 enrolled · United States
  3. Mar 28, 2026Phase 2 study in HypertensionNCT07511361 · 140 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in HypertensionNCT07511361

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Kardigan leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07511361Hypertension · United States2RecruitingDec 2026140
NCT06864104Hypertension · United States2CompletedJan 12, 2026206

How it is read

Names in the registry

  • “Tonlamarsen”, 2 entries
  • “ION904”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.